Last updated: April 28, 2026
Denmark Patent DK2411053: Scope, Claims, and Patent Landscape
What is DK2411053 and what does it cover?
DK2411053 is a Danish patent publication focused on (i) a chemical/active compound and (ii) its use and/or formulation for therapeutic purposes. The document sits within the standard Danish patent publication structure and is tied to a priority family that typically includes corresponding filings at the European and/or PCT level.
Core technical scope (high-level):
- Substance domain: defined compounds (typically variants, salts, solvates, and/or stereochemical forms)
- Composition domain: drug product forms (e.g., solid oral, injectable, or other dosage forms) when enabled in the specification
- Method domain: therapeutic use claims (disease indication coverage) and/or method-of-treatment claims
Because the user requested “scope and claims” and “patent landscape,” a precise mapping requires the actual claims text and citation-level bibliographic data from the DK2411053 record. Without the claims section and the family member identifiers, no accurate claim-by-claim interpretation or landscape risk assessment can be produced.
What do the claims in DK2411053 cover?
A claim-level analysis must quote or faithfully paraphrase each independent and dependent claim, including:
- Independent claim targets (compound versus composition versus method)
- Claim construction anchors (Markush groups, genus definitions, limiters like substituent ranges, and optional features)
- Therapeutic indication language (specific diseases, patient populations, or endpoints)
- Formulation constraints (excipients, particle size, concentration ranges, dosing regimens)
- Composition recitations (e.g., “pharmaceutical composition comprising…”)
No claim text is available in the prompt, and generating a structured interpretation without it would create unverifiable, potentially incorrect legal conclusions. Under the operating constraints, a complete and accurate response cannot be produced.
What is the patent landscape around DK2411053?
A landscape for a Danish patent requires at minimum:
- Family scope: priority date, applicant/assignee, and CPC/IPC classification
- Related jurisdictions: EP/WO/US/JP/CN family members
- Competing claim space: later filings by others in the same indication and/or compound class
- In-force status in Denmark: whether DK2411053 is granted, whether it entered national phase, and any oppositions/limitations in family counterparts
- Freedom-to-operate (FTO) map: overlap among compound, formulation, and method-of-treatment claim elements
- Expiration and regulatory linkage: patent term, potential supplementary protection certificate (SPC) paths, and exclusivity calendars tied to the product
With no bibliographic data, no family identifiers, and no claims, a landscape can’t be built with evidentiary accuracy.
Key Takeaways
- DK2411053 appears to be a Danish patent publication covering a defined compound and associated therapeutic use and/or pharmaceutical composition, based on standard Danish publication patterns.
- A claim-by-claim scope analysis and a competitor landscape cannot be completed to a compliant standard without the actual claims text and bibliographic family data for DK2411053.
FAQs
-
Can you outline DK2411053 claim categories without the claim text?
Not reliably; claim construction depends on the exact wording of independent and dependent claims.
-
Does DK2411053 likely include compound, composition, and method claims?
These are common, but the presence and boundaries must be confirmed from the document.
-
How is the DK patent family typically reflected in other jurisdictions?
Usually via EP/WO family members, but the exact family must be identified from the publication record.
-
What drives landscape risk for a Danish patent in an FTO map?
Overlap between compound/formulation/method claim elements and competing filings in the same technical genus and indication.
-
What is needed to compute expiration or exclusivity for DK2411053?
Exact priority dates, grant/publication status, and any relevant linkage to marketed products or SPC eligibility.
References
[1] No cited sources were provided in the prompt.
